Department of Commerce at the time of the Department's initial promulgation.

EFFECTIVE DATE: The allotments are effective October 1, 1998.

FISCAL YEAR 1999 FEDERAL ALLOTMENTS TO STATES FOR SOCIAL SERVICES—TITLE XX BLOCK GRANTS

	Initial FY 99 Allotment	Revised FY 99 allotment
ALABAMA	38,121,040	30,576,918
ALASKA	5,415,275	4,343,597
AMERICAN SAMOA	88,560	71,034
ARIZONA	39,503,853	31,686,074
ARKANSAS	22,392,654	17,961,167
CALIFORNIA	284,395,631	228,113,973
COLORADO	34,106,421	27,356,789
CONNECTICUT	29,208,585	23,428,231
DELAWARE	6,467,998	5,187,987
DISTRICT OF COLUMBIA	4,844,307	3,885,623
FLORIDA	128,467,816	103,044,143
GEORGIA	65,598,878	52,616,915
GUAM	410,345	329,138
HAWAII	10,562,909	8,472,518
IDAHO	10,607,516	8,508,297
ILLINOIS	105,691,543	84,775,276
INDIANA	52,109,758	41,797,281
IOWA	25,443,765	20,408,465
KANSAS	22,945,779	18,404,829
KENTUCKY	34,650,625	27,793,295
LOUISIANA	38,816,907	31,135,074
MAINE	11,089,270	8,894.713
MARYLAND	45,249,220	36,294,437
MASSACHUSETTS	54,349,023	43,593,397
MICHIGAN	85,591,682	68,653,160
MINNESOTA	41,555,770	33,331,918
MISSISSIPPI	24,230,457	19,435,270
MISSOURI	47,809,654	38,348,164
MONTANA	7,841,890	6,289,987
NEBRASKA	14,738,113	11,821,453
NEVADA	14,300,966	11,470,817
NEW HAMPSHIRE	10,366,639	8,315,090
NEW JERSEY	71,263,952	57,160,876
NEW MEXICO	15,282,317	12,257,959
NEW YORK	162,235,224	130,129,009
NORTH CAROLINA	65,331,237	52,402,240
NORTH DAKOTA	5,745,366	4,608,363
N. MARIANA ISLANDS	82,069	65,828
OHIO	99,678,535	79,952,237
OKLAHOMA	29,449,462	23,621,438
OREGON	28,584,089	22,927,322
PENNSYLVANIA	107,556,110	86,270,846
PUERTO RICO	12,310,345	9,874,138
RHODE ISLAND	8,832,162	7,084,284
SOUTH CAROLINA	33,000,170	26,469,464
SOUTH DAKOTA	6,530,447	5,238,077
TENNESSEE	47,461,721	38,069,086
TEXAS	170,648,082	136,876,970
UTAH	17,842,752	14,311,686
VERMONT	5,254,691	4,214,792
VIRGIN ISLANDS	410,345	329,138
VIRGINIA	59,550,185	47,765,253
WASHINGTON	49,361,974	39,593,281
WEST VIRGINIA	16,290,433	13,066,570
WISCONSIN	46,034,301	36,924,152
WYOMING	4,291,182	3,441,961
Total	2,380,000,000	1,909,000,000

Dated: November 4, 1998.

Donald Sykes,

Director, Office of Community Services.

[FR Doc. 98–30564 Filed 11–13–98; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Renewals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs. The Commissioner has determined that it is in the public interest to renew the charters of the committees listed below for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed below. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92–463 (5 U.S.C. app. 2)).

DATE: Authority for these committees will expire on the dates indicated below unless the Commissioner formally determines that renewal is in the public interest.

Name of committee	Date of expiration
Advisory Committee for Pharmaceutical Science	January 22, 2000
Medical Imaging Drugs Advisory Committee	February 28, 2000
Gastrointestinal Drugs Advisory Committee	March 3, 2000
Advisory Committee for Reproductive Health Drugs	March 23, 2000
Arthritis Advisory Committee	April 5, 2000
Veterinary Medicine Advisory Committee	April 24, 2000
Anesthetic and Life Support Drugs Advisory Committee	May 1, 2000
Blood Products Advisory Committee	May 13, 2000
Pulmonary-Allergy Drugs Advisory Committee	May 30, 2000
Drug Abuse Advisory Committee	May 31, 2000
Science Advisory Board to the National Center for Toxicological and Research	June 2, 2000
Peripheral and Central Nervous System Drugs Advisory Committee	June 4, 2000
Psychopharmacologic Drugs Advisory Committee	June 4, 2000
Transmissible Spongiform Encephalopathies Advisory Committee	June 9, 2000
Science Board to the Food and Drug Administration	June 26, 2000
Allergenic Products Advisory Committee	July 9, 2000
Cardiovascular and Renal Drugs Advisory Committee	August 27, 2000
Endocrinologic and Metabolic Drugs Advisory Committee	August 27, 2000
Oncologic Drugs Advisory Committee	September 1, 2000
Anti-Infective Drugs Advisory Committee	October 7, 2000
Dermatologic and Ophthalmic Drugs Advisory Committee	October 7, 2000
Biological Response Modifiers Advisory Committee	October 28, 2000

FOR FURTHER INFORMATION CONTACT: Donna M. Combs, Committee Management Office (HFA–306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4820.

Dated: November 5, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–30457 Filed 11–13–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Veterinary Medicine Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Veterinary Medicine Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on December 10 and 11, 1998, 8:30 a.m. to 4 p.m.

Location: Holiday Inn, Two Montgomery Village Ave., Gaithersburg, MD.

Contact: Jacquelyn L. Pace, Center for Veterinary Medicine (HFV–200), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–6650, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12546. Additional information about the meeting will be provided on the Center for Veterinary Medicine Internet Home Page (http://www.fda.gov/cvm) after November 1, 1998. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss a proposed framework on how to evaluate the potential public health hazard from resistant pathogens and resistance genes associated with the use of antimicrobials in food animals.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by December 3, 1998. Oral presentations from the public are tentatively scheduled for the morning of December 11, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before December 3, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: November 5, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–30548 Filed 11–13–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Oncologic Drugs Advisory Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Oncologic Drugs Advisory Committee. This meeting was announced in the **Federal Register** of October 29, 1998. The meeting will be open to the public. The amendment is being made to cancel the entire session on November 17, 1998. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Karen M. Templeton–Somers, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7001, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12542.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of October 29, 1998 (63 FR 58054), FDA announced that a meeting of the Oncologic Drugs Advisory Committee would be held on November 16 and 17, 1998. On page 58054, beginning in the second column, the *Date and Time*, *Agenda*, and *Procedure* portions of this meeting are amended and the *Closed Committee Deliberations* portion is removed to read as follows:

Date and Time: The meeting will be held on November 16, 1998, 8:30 a.m. to 5:30 p.m.

Agenda: On November 16, 1998, the committee will discuss: (1) New drug application (NDA) 20–886 Panretin® (alitretinoin) Gel 0.1%, Ligand Pharmaceuticals, Inc., indicated for the first-line topical treatment of cutaneous lesions in patients with acquired immune deficiency syndrome (AIDS)-related Kaposi's sarcoma; and (2) NDA 21–041 DepoCyt™ (cytarabine liposome injection), DepoTech Corp., indicated for the intrathecal treatment of lymphomatous meningitis.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by November 9, 1998. Oral presentations from the public will be scheduled between approximately 8:45 a.m. and 9 a.m., and 1:45 p.m. and 2 p.m. on November 16, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 9, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. After the scientific presentations, an open public session will be conducted for interested persons who have submitted their request to speak by November 9, 1998, to address issues specific to the submission or topic before the committee.

Dated: November 5, 1998

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–30453 Filed 11–13–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0535]

Agency Information Collection Activities; Announcement of OMB Approval; Protection of Human Subjects; Recordkeeping Requirements for Institutional Review Boards (IRB's)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Protection of Human Subjects; Recordkeeping Requirements for Institutional Review Boards (IRB's)'' has been approved by the Office of Management and Budget (OMB) under